Navigation Links
TGen finds therapeutic targets for rare cancer in children
Date:9/1/2010

PHOENIX, Ariz. Aug. 31, 2010 The first study of Ewing's sarcoma that screened hundreds of genes based on how they affect cell growth has identified two potential anti-cancer drug targets, according to a scientific paper by the Translational Genomics Research Institute (TGen) published this month in the journal Molecular Cancer.

Ewing's sarcomas are rare, but aggressive cancer lesions that occur most frequently in the bones of teenagers. They represent nearly 3 percent of all childhood cancers. Patients are treated with a combination of surgery, radiation and chemotherapy. This cancer can reoccur after surgical removal, and often spreads to the lungs, other bones and bone marrow. Once it spreads, or metastasizes, only 1 in 5 patients survive more than 5 years.

These lesions harbor unique chromosomal abnormalities that give rise to fusion genes that act as cancer-inducing proteins, or oncoproteins.

TGen researchers used RNAi-based phenotypic, or loss-of-function screening, a method of silencing hundreds of individual genes in a high-throughput format, to analyze 572 kinases that are expressed in human cells. Kinases are enzymes that modify other proteins. Using this technique, the authors discovered two protein kinases with important roles in the growth and survival of Ewing's sarcoma cells. Cancer cells died when investigators stopped the normal function of the two protein kinases called STK10 and TNK2.

"RNAi-based phenotypic profiling proved to be a powerful gene target discovery strategy, leading to successful identification and validation of STK10 and TNK2 as two novel potential therapeutic targets for Ewing's sarcoma," said Dr. David Azorsa, a TGen Senior Investigator and the paper's senior author.

This was the first study demonstrating the use of this kind of phenotypic profiling to identify unique kinase targets for Ewing's sarcoma, according to the paper.

By identifying kinases that regulate the growth of Ewing's sarcoma cells, TGen investigators anticipate a rapid translation of their discoveries into clinical drug trials and specific remedies for individual patients, advancing the prospects of personalized medicine.

"We undertook this study with the goal of identifying specific kinases that can be targeted to modulate Ewing's sarcoma cell growth and survival," said Dr. Shilpi Arora, a TGen Staff Scientist and the paper's lead author. "In addition to the identification of specific kinase targets, we were able to obtain a better understanding of contextual vulnerabilities in Ewing's sarcoma."


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Study finds an increased risk of death in men with insomnia and a short sleep duration
2. FDA Finds Rodents, Manure Piles at Farms in Egg Recall
3. Study finds asking about pregnancy coercion and intimate-partner violence can reduce their incidence
4. Location determines social network influence, CCNY-led team finds
5. Herpes Drugs Wont Raise Birth Defect Risk, Study Finds
6. Mumps vaccine coverage should be improved, study finds
7. Survey of American women finds STD vaccine viewed positively
8. Study Finds Even a Little Cigarette Smoke Harms Airway
9. New study finds new connection between yoga and mood
10. Global media campaign finds hidden children with rare, fatal aging disorder
11. VCU Massey research finds new link between inflammation and cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), creator ... tool, and the Cancer Patient Education Network (CPEN), an independent professional organization that ... new strategic alliance. , As CPEN’s strategic partner, HLI will help support ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical ... to physician colleagues, skilled nursing facility medical directors and other clinicians at various ... Wound Care." , "At many of these conferences we get to educate other ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated ... latest FDA requirements, which stipulates new criteria regarding medical device manufacture ... Medical ID jewelry such as Medical ID Bracelets, can rest assured ... of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process ...
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance ... a medical-grade battery-powered display stand specifically designed for endoscopy environments. An ... technology into a clinical solution to support the improvement of patient ... Innovative Design ... Wireless Solution ...
Breaking Medicine Technology: